1. Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy 
Sophie Papa, MRCP, PhD, Sanjay Popat, FRCP, PhD, Riyaz Shah, FRCP, PhD, A. Toby Prevost, PhD, Rohit Lal, MRCP, PhD, Blair McLennan, BAppSc, Paul Cane, FRCPath, Loic Lang-Lazdunski, MD, Zaid Viney, MRCP, FRCR, Joel T. Dunn, PhD, Sally Barrington, FRCP, FRCR, David Landau, MRCP, James Spicer, FRCP, PhD 
Journal of Thoracic Oncology 
Volume 8, Issue 6, Pages (June 2013)
DOI: /JTO.0b013e31828c2b26
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Kaplan–Meier plots for (A), PFS and (B), OS. Fifty-three patients provided data for both analyses. Median PFS was 5.1 months (95% CI: 3.5–6.7 months), with 36% (95% CI: 22%–49%) of patients progression-free at 6 months. Median OS was 9.0 months (95% CI: 6.7–11.3 months). PFS, progression-free survival; OS, overall survival; CI, confidence interval.
Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828c2b26)
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Best response by Response Evaluation Criteria in Solid Tumors criteria modified for mesothelioma. Each bar represents an individual patient. Two patients were not evaluable because of nontarget lesion progression at 8 weeks, and 12 patients did not complete the first response assessment at 8 weeks (white = partial response; black = stable disease; hatched = progressive disease).
Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e31828c2b26)
Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions